Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 13.8% in September

Generation Bio Co. (NASDAQ:GBIO) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 2,140,000 shares, a growth of 13.8% from the August 31st total of 1,880,000 shares. Based on an average daily trading volume, of 116,800 shares, the short-interest ratio is currently 18.3 days. Approximately 4.4% of the company’s stock are short sold.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a report on Thursday, August 8th. Wedbush restated an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.50.

Generation Bio Stock Up 1.6 %

Shares of Generation Bio stock opened at $2.47 on Tuesday. The stock has a market capitalization of $164.33 million, a P/E ratio of -0.97 and a beta of 2.81. The stock has a 50 day moving average price of $2.64 and a two-hundred day moving average price of $2.97. Generation Bio has a 12-month low of $0.86 and a 12-month high of $4.65.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Wednesday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The company had revenue of $4.09 million for the quarter, compared to the consensus estimate of $3.23 million. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. Sell-side analysts anticipate that Generation Bio will post -1.8 earnings per share for the current year.

Institutional Investors Weigh In On Generation Bio

Large investors have recently added to or reduced their stakes in the stock. PFG Advisors bought a new stake in Generation Bio during the first quarter worth approximately $41,000. Cubist Systematic Strategies LLC boosted its position in shares of Generation Bio by 91.0% in the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after acquiring an additional 9,075 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Generation Bio in the first quarter valued at approximately $74,000. American Century Companies Inc. boosted its position in shares of Generation Bio by 199.3% in the second quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after acquiring an additional 21,167 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Generation Bio by 7.4% in the second quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock valued at $222,000 after acquiring an additional 5,430 shares during the period. Institutional investors own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.